Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Escalated BEACOPP vs chemotherapy including ABVD Adverse event: secondary malignancies: AML or MDS · Patients with early unfavourable or advanced stage HL Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for… (2017) · Cochrane | RR 3.9 [1.36, 11.21] | 5 studies · 3332 participants | Low |
Escalated BEACOPP vs chemotherapy including ABVD Adverse event: infertility (secondary amenorrhoea) · Patients with early unfavourable or advanced stage HL Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for… (2017) · Cochrane | RR 1.37 [0.83, 2.26] | 1 study · 106 participants | Very low |
Escalated BEACOPP vs chemotherapy including ABVD Quality of life · Patients with early unfavourable or advanced stage HL Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for… (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy alone vs same chemotherapy plus radiotherapy Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | OR 0.43 [0.23, 0.82] | 3 studies · 1011 participants | Low |
Fewer vs more courses of chemotherapy (with or without radiotherapy Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | OR 1.1 [0.74, 1.62] | 3 studies · 2403 participants | Moderate |
Fewer vs more courses of chemotherapy (with or without radiotherapy Death · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 0.99 [0.73, 1.34] | 3 studies · 2403 participants | High |
Fewer vs more courses of chemotherapy (with or without radiotherapy Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 1.15 [0.91, 1.45] | 3 studies · 2403 participants | High |
Dose‐intensified chemotherapy vs ABVD‐like chemotherapy (with or without radiotherapy Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (advanced stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | OR 1.37 [0.89, 2.1] | 7 studies · 2996 participants | Low |
Dose‐intensified chemotherapy vs ABVD‐like chemotherapy (with or without radiotherapy Death · Patients with untreated Hodgkin lymphoma (advanced stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 0.85 [0.7, 1.04] | 7 studies · 2996 participants | Moderate |
Dose‐intensified chemotherapy vs ABVD‐like chemotherapy (with or without radiotherapy Progression/relapse · Patients with untreated Hodgkin lymphoma (advanced stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 0.82 [0.7, 0.95] | 7 studies · 2996 participants | Moderate |
Chemotherapy alone vs same chemotherapy plus radiotherapy Death · Patients with untreated Hodgkin lymphoma (early and advanced stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 0.71 [0.46, 1.11] | 3 studies · 1011 participants | Moderate |
Chemotherapy alone vs same chemotherapy plus radiotherapy Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 1.31 [0.99, 1.73] | 3 studies · 1011 participants | Moderate |
Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | OR 0.86 [0.64, 1.16] | 4 studies · 2397 participants | Low |
Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation Death · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 0.89 [0.7, 1.12] | 4 studies · 2397 participants | High |
Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 0.99 [0.81, 1.21] | 4 studies · 2397 participants | High |
Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | OR 1.03 [0.71, 1.5] | 3 studies · 2962 participants | Low |
Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation Death · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 0.91 [0.65, 1.28] | 3 studies · 2962 participants | High |
Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages) Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second… (2017) · Cochrane | HR 1.2 [0.97, 1.48] | 3 studies · 2962 participants | High |
Pathogen‐reduced platelets vs standard platelets Number of participants with 'any bleeding' event(s) (WHO grade 1 to 4 or equivalent) ‐ · thrombocytopenia Pathogen‐reduced platelets for the prevention of bleeding (2017) · Cochrane | RR 1.09 [1.02, 1.15] | 5 studies · 1085 participants | Low |
Pathogen‐reduced platelets vs standard platelets Number of participants with 'clinically significant' bleeding event(s) (WHO grade ≥ 2 or equivalent) ‐ · thrombocytopenia Pathogen‐reduced platelets for the prevention of bleeding (2017) · Cochrane | RR 1.1 [0.97, 1.25] | 5 studies · 1392 participants | Moderate |
Pathogen‐reduced platelets vs standard platelets Number of participants with 'severe' bleeding event(s) (WHO grade ≥ 3 or equivalent) ‐ · thrombocytopenia Pathogen‐reduced platelets for the prevention of bleeding (2017) · Cochrane | RR 1.24 [0.76, 2.02] | 6 studies · 1495 participants | Moderate |
Pathogen‐reduced platelets vs standard platelets All‐cause mortality · thrombocytopenia Pathogen‐reduced platelets for the prevention of bleeding (2017) · Cochrane | RR 0.81 [0.5, 1.29] | 6 studies · 1509 participants | Moderate |
Pathogen‐reduced platelets vs standard platelets Number of participants with a serious adverse event · thrombocytopenia Pathogen‐reduced platelets for the prevention of bleeding (2017) · Cochrane | RR 1.09 [0.88, 1.35] | 7 studies · 1340 participants | Moderate |
Pathogen‐reduced platelets vs standard platelets Number of participants experiencing platelet refractoriness · thrombocytopenia Pathogen‐reduced platelets for the prevention of bleeding (2017) · Cochrane | RR 2.94 [2.08, 4.16] | 7 studies · 1525 participants | High |
Pathogen‐reduced platelets vs standard platelets Number of platelet transfusions per participant Multiple platelet transfusion trials · thrombocytopenia Pathogen‐reduced platelets for the prevention of bleeding (2017) · Cochrane | no estimate extracted | 6 studies · 1509 participants | High |
Thrombopoietin mimetics vs placebo Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | no estimate extracted | 2 studies · 282 participants | Ungraded |
Thrombopoietin mimetics vs placebo Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | RR 0.97 [0.73, 1.27] | 6 studies · 746 participants | Low |
Thrombopoietin mimetics vs placebo Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | RR 1.02 [0.59, 1.77] | 5 studies · 372 participants | Very low |
Thrombopoietin mimetics vs placebo Incidence of bleeding events · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | RR 0.92 [0.86, 0.98] | 5 studies · 390 participants | Moderate |
Thrombopoietin mimetics vs placebo Transfusion requirement · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | RR 0.83 [0.66, 1.05] | 4 studies · 358 participants | Low |
Thrombopoietin mimetics vs placebo Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetics vs placebo All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | RR 1.01 [0.96, 1.07] | 5 studies · 390 participants | Moderate |
Thrombopoietin mimetics vs placebo Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia Thrombopoietin mimetics for patients with myelodysplastic syndromes (2017) · Cochrane | RR 0.89 [0.54, 1.46] | 4 studies · 356 participants | Very low |
Intervention NR All‐cause mortality · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | RR 1.35 [0.53, 3.45] | 1 study · 26 participants | Low |
Intervention NR Number of patients with at least one severe/life‐threatening bleeding episode · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | 1 study · 62 participants | Very low |
Intervention NR Number of treatment cycles with at least one bleeding episode ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of days on which bleeding occurred ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR The amount of bleeding ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life score ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with at least one bleeding episode of any severity · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | RR 0.62 [0.22, 1.78] | 2 studies · 206 participants | Very low |
Intervention NR Number of patients with at least one severe/life‐threatening bleeding episode · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | RR 0.36 [0.06, 2.06] | 2 studies · 206 participants | Very low |
Intervention NR Number of treatment cycles with at least one bleeding episode ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of days on which bleeding occurred ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR The amount of bleeding ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life score ‐ not measured · patients with solid tumours without thrombocytopenia before chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival ‐ not measured · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with at least one bleeding episode of any severity · patients with solid tumours with thrombocytopenia during chemotherapy Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in… (2017) · Cochrane | RR 2.8 [0.17, 47.53] | 1 study · 62 participants | Very low |
G‐CSF vs placebo Overall survival · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | HR 0.8 [0.44, 1.46] | 1 study · 64 participants | Very low |
GM‐CSF vs placebo Time to progression to AML · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |
GM‐CSF vs placebo Quality of life · newly diagnosed patients with myelodysplastic syndromes Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with… (2016) · Cochrane | no estimate extracted | NR | No studies |